Kang Mee Joo, Yun E Hwa, Jung Kyu-Won, Park Sang-Jae
Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea.
Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
Ann Hepatobiliary Pancreat Surg. 2022 Aug 31;26(3):220-228. doi: 10.14701/ahbps.22-041. Epub 2022 Jul 29.
BACKGROUNDS/AIMS: In Korea, pancreatic cancer and "gallbladder and extrahepatic bile duct cancer" were ranked the 8th and 9th most frequent cancers in 2019 and the 4th and 6th most common causes of cancer deaths in 2020, respectively.
This review provides national cancer statistics and secular trends of 207,521 patients with gallbladder (n = 44,178), extrahepatic bile duct (n = 61,856), and pancreatic cancer (n = 101,487) between 1999 and 2019 in Korea.
The crude incidence rate in both sexes increased in the gallbladder (2.8 to 5.4 per 100,000), extrahepatic bile duct (3.6 to 9.0), and pancreatic cancer (5.5 to 15.8). The age-standardized incidence rate in both sexes significantly increased in the extrahepatic bile duct (3.7 to 4.1) and pancreatic (5.6 to 7.6) cancers but decreased in gallbladder cancer (2.9 to 2.4). The overall 5-year relative survival rate increased in the gallbladder (21.8% to 30.6%), extrahepatic bile duct (23.1% to 27.5%), and pancreatic (8.5% to 13.3%) cancers. Between 2006 and 2019, the proportion of localized or regional stages remained stable. The proportion of surgical treatment within the first 4 months after diagnosis was relatively higher in the gallbladder (42.2%) and extrahepatic bile duct (45.9%) cancers than in pancreatic cancer (22.2%).
The crude incidence and mortality rates of the gallbladder, extrahepatic bile duct, and pancreatic cancer are steadily increasing in Korea, and the prognosis remains poor. Early detection, active application of surgical treatment, and minimization of the proportion of untreated patients are required to improve the survival rates of these cancers.
背景/目的：在韩国，胰腺癌和“胆囊及肝外胆管癌”在2019年分别位列发病率第8和第9位常见癌症，在2020年分别是癌症死亡的第4和第6大常见原因。
本综述提供了1999年至2019年韩国207,521例胆囊癌（n = 44,178）、肝外胆管癌（n = 61,856）和胰腺癌（n = 101,487）患者的国家癌症统计数据及长期趋势。
胆囊癌（从每10万人2.8例增至5.4例）、肝外胆管癌（从3.6例增至9.0例）和胰腺癌（从5.5例增至15.8例）的男女粗发病率均有所上升。肝外胆管癌（从3.7例增至4.1例）和胰腺癌（从5.6例增至7.6例）的男女年龄标准化发病率显著上升，而胆囊癌（从2.9例降至2.4例）则下降。胆囊癌（从21.8%升至30.6%）、肝外胆管癌（从23.1%升至27.5%）和胰腺癌（从8.5%升至13.3%）的总体5年相对生存率均有所提高。2006年至2019年期间，局限性或区域性分期的比例保持稳定。胆囊癌（42.2%）和肝外胆管癌（45.9%）在诊断后前4个月内接受手术治疗的比例相对高于胰腺癌（22.2%）。
在韩国，胆囊癌、肝外胆管癌和胰腺癌的粗发病率和死亡率在稳步上升，预后仍然较差。需要早期检测、积极应用手术治疗并尽量减少未治疗患者的比例，以提高这些癌症的生存率。
